Enhancing CD19 Chimeric Antigen Receptor T Cells Through Memory-Enriched T Cells.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36507801.
- Also identified by DOI 10.1158/1078-0432.CCR-22-3232 and PMC identifier 9957814.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chimeric antigen receptor T (CAR-T) cells directed against CD19 have transformed the therapy of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). A recent study reports promising activity and safety of CD19 CAR-T cells generated from naïve, stem, and central memory T cells in adults with R/R B-ALL. See related article by Aldoss et al., p. 742.
Medical subject headings
- Receptors, Chimeric Antigen
- Precursor Cell Lymphoblastic Leukemia-Lymphoma